Schmidt J G
Centre for Clinical Epidemiology, University of Newcastle, NSW, Australia.
J Clin Epidemiol. 1990;43(3):215-25. doi: 10.1016/0895-4356(90)90002-7.
The present paper analyses the epidemiologic effects of mass breast cancer screening. Mass mammography may possibly achieve a breast cancer mortality reduction in relative risk terms. However, this does not necessarily represent a net benefit. It is argued that the benefits and adverse effects of a screening programme must be measured in terms of absolute risks. According to this measure, the mortality reduction achieved by a mass breast screening programme is only one death per approx. 15,000 women-years. Many thousands of mammograms are needed to prevent one cancer death, and for each woman who can derive a direct benefit in terms of a prevented breast cancer death, hundreds of women have to suffer the anxiety of a positive screening mammography. Moreover, it is possible that adverse effects of breast cancer screening may contribute to mortality from other causes. Even with the assumption that screening can save lives, the net health effect of mass breast cancer screening is questionable and appears to be rather detrimental. It may be an error to recommend mass breast screening.
本文分析了大规模乳腺癌筛查的流行病学效果。大规模乳腺钼靶检查在相对风险方面可能会降低乳腺癌死亡率。然而,这不一定代表净效益。有人认为,筛查计划的益处和不良影响必须根据绝对风险来衡量。根据这一衡量标准,大规模乳腺癌筛查计划实现的死亡率降低仅为每约15000妇女年1例死亡。需要进行数千次乳腺钼靶检查才能预防1例癌症死亡,对于每一位能从预防乳腺癌死亡中直接获益的女性来说,数百名女性不得不承受乳腺钼靶筛查呈阳性带来的焦虑。此外,乳腺癌筛查的不良影响可能会导致因其他原因造成的死亡。即使假设筛查可以挽救生命,大规模乳腺癌筛查的净健康效果也值得怀疑,而且似乎相当有害。推荐大规模乳腺癌筛查可能是一个错误。